Kyle Fetter, Vice President & General Manager of Diagnostic Services at XIFIN, will be speaking at this year's G2 Intelligence Lab Leadership Summit in Atlanta, GA on Friday, December 8th, 2017.
The summit will focus on The Protecting Access to Medicare Act (PAMA); the effect this legislation has on clinical laboratory reimbursement, how companies can remain compliant, and future changes to current revenue strategies.
Key takeaways from this summit will include:
- Impact of PAMA on laboratory fee schedules
- How to maximize reimbursement revenue
- How to manage costs
- Practical strategies to manage financial stability
The most urgent issue of PAMA is the Part B Clinical Laboratory Fee Schedule (CLFS), which is set to change rates for diagnostic laboratories. This substantial shift in lab test pricing will go into effect on January 1, 2018.
Mr. Fetter will be presenting on "Drastic Fee Cuts and Decreasing Coverage: Reimbursement and Regulatory Challenges for Diagnostics in 2018" leveraging his more than 10 years in the biotech industry, and has implemented and overseen the commercialization, billing, and reimbursement processes for over 70 unique molecular diagnostic companies.
Other experienced speakers include Jeffrey H. Myers, CPA, Vice President of Consulting at Accumen, Inc., who has financially managed healthcare administration for more than 20 years; Ellen Neiduski, Managing Director at FTI Consulting, who has over 30 years of healthcare management experience; Diana Voorhees, Principal, DV & Associates, Inc. which she developed over 20 years ago; and attorney Andrew B. Wachler, from at Wachler & Associates, PC, who has practiced healthcare law over for 20 years.
Are you attending the event? If so, please schedule time to connect with Kyle.